The Cost-Effectiveness of Cyclooxygenase-2 Selective Inhibitors in the Management of Chronic Arthritis

Annals of Internal Medicine

Volumn 138, Issue 10, 2003, Pages

  Spiegel, Brennan M R ^b   Targownik, Laura ^b   Dulai, Gareth S ^b   Gralnek, Ian M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; CYCLOOXYGENASE 2; ISOENZYME; LACTONE; MEMBRANE PROTEIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS2 PROTEIN, HUMAN; PYRAZOLE DERIVATIVE; SULFONAMIDE; SULFONE;

ARTHRALGIA; CARDIOVASCULAR DISEASE; CHRONIC ARTHRITIS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIGESTIVE SYSTEM ULCER; DRUG COST; DYSPEPSIA; GASTROINTESTINAL TOXICITY; HEALTH CARE COST; HUMAN; META ANALYSIS; OSTEOARTHRITIS; PEPTIC ULCER BLEEDING; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; RHEUMATOID ARTHRITIS; RISK REDUCTION; CHEMICALLY INDUCED DISORDER; CHRONIC DISEASE; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; DRUG ANTAGONISM; ECONOMICS; PEPTIC ULCER; RECURRENT DISEASE; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; COST-BENEFIT ANALYSIS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DECISION SUPPORT TECHNIQUES; HUMANS; ISOENZYMES; LACTONES; MEMBRANE PROTEINS; OSTEOARTHRITIS; PEPTIC ULCER; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; QUALITY-ADJUSTED LIFE YEARS; RECURRENCE; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SULFONAMIDES; SULFONES;

EID: 1642483560     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-138-10-200305200-00007     Document Type: Review

References (91)

1. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 1998;41:778-99. [PMID: 9588729]
2. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999;340:1888-99. [PMID: 10369853]
3. March LM, Bachmeier CJ. Economics of osteoarthritis: a global perspective. Baillieres Clin Rheumatol. 1997;11:817-34. [PMID: 9429738]
4. Marra CA, Esdaile JM, Sun H, Anis AH. The cost of COX inhibitors: how selective should we be? [Editorial] J Rheumatol. 2000;27:2731-3. [PMID: 11128654]
5. Hawkey CJ. Nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology. 2000;119:521-35. [PMID: 10930388]
6. Straus WL, Ofman JJ, MacLean C, Morton S, Berger ML, Roth EA, et al. Do NSAIDs cause dyspepsia? A meta-analysis evaluating alternative dyspepsia definitions. Am J Gastroenterol. 2002;97:1951-8. [PMID: 12190159]
7. Ofman JJ, MacLean CH, Straus WL, Morton SC, Berger ML, Roth EA, et al. A meta-analysis of dyspepsia of nonsteroidal anti-inflammatory drugs. Arthritis Care Res. [In press].
8. Larkai EN, Smith JL, Lidsky MD, Graham DY. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol. 1987;82:1153-8. [PMID: 3499815]
9. Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch Intern Med. 2000;160:2998-3003. [PMID: 11041909]
10. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000; 343:1520-8, 2 p following 1528. [PMID: 11087881]
11. Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA. 1999;282:1929-33. [PMID: 10580458]
12. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284: 1247-55. [PMID: 10979111]
13. Goldstein JL, Eisen GM, Stenson W, Agrawal N, Bello AE, Fort JG, et al. Significant reduction in serious upper gastrointestinal (UGI) events with celecoxib, a COX-2 specific inhibitor, compared with conventional NSAIDs: the SUCCESS 1 trial [Abstract]. Gastroenterology. 2001;120:A105. Abstract no. 554.
14. Arthritis Pain Society. Guidelines for the Management of Pain in Osteoarthritis, Rheumatoid Arthritis, and Juvenile Chronic Arthritis. March 2002. Accessed at www.ampainsoc.org/whatsnew/031502.htm in April 2003.
15. Laine L, Wogen J, Boccuzzi S. Do coxibs decrease G1 health care resource utilization as compared to traditional NSAIDs? [Abstract] Gastroenterology. 2002;122:A53. Abstract no. 442.
16. Laine L. GI medical co-therapy use in 14,001 patients switching from chronic traditional NSAID therapy to chronic coxib therapy [Abstract]. Gastroenterology. 2002;122:A53. Abstract no. 441.
17. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286:954-9. [PMID: 11509060]
18. Jüni P, Dieppe P, Egger M. Risk of myocardial infarction associated with selective COX-2 inhibitors: questions remain [Letter]. Arch Intern Med. 2002; 162:2639-40; author reply 2640-2. [PMID: 12456259]
19. U.S. Food and Drug Administration. Cardiovascular Safety Review. Rockville, MD: U.S. Food and Drug Administration; 2001. Accessed at www.fda.gov /ohrms/dockets/ac/01/briefing/3677b2_06_cardio.pdf in December 2002.
20. U.S. Food and Drug Administration. OPDRA Postmarketing Safety Review. Rockville, MD: U.S. Food and Drug Administration; 2001. Accessed at www.fda.gov/ohrms/dockers/ac/01/briefing/3677b1.htm in April 2003.
21. U.S. Food and Drug Administration. FDA Advisory Committee Briefing Document NDA 21-042, s007: VIOXX Gastrointestinal Safety. Rockville, MD: U.S. Food and Drug Administration; 2001. Accessed at www.fda.gov/ohrms /dockets/ac/01/briefing/3677b2_03_med.pdf in December 2002.
22. Drummond MF, Richardson WS, O'Brien BJ, Levine M, Heyland D. Users' guides to the medical literature. XIII. How to use an article on economic analysis of clinical practice. A. Are the results of the study valid? Evidence-Based Medicine Working Group. JAMA. 1997;277:1552-7. [PMID: 9153371]
23. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet. 2002;359:14-22. [PMID: 11809181]
24. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995;123: 241-9. [PMID: 7611589]
25. Danesh J, Lawrence M, Murphy M, Roberts S, Collins R. Systematic review of the epidemiological evidence on Helicobacter pylori infection and nonulcer or uninvestigated dyspepsia. Arch Intern Med. 2000;160:1192-8. [PMID: 10789614]
26. Moayyedi P, Soo S, Deeks JJ, Delaney BC, Innes M, Forman D. A systematic review and economic analysis of the cost-effectiveness of H. pylori eradication therapy in non-ulcer dyspepsia (NUD) [Abstract]. Gastroenterology 2000; 118:A471. Abstract no. 2561.
27. Laine L, Schoenfeld P, Fennerty MB. Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials. Ann Intern Med. 2001;134:361-9. [PMID: 11242496]
28. Jaakkimainen RL, Boyle E, Tudiver F. Is Helicobacter pylori associated with non-ulcer dyspepsia and will eradication improve symptoms? A meta-analysis. BMJ. 1999;319:1040-4. [PMID: 10521198]
29. Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ. Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study. Aliment Pharmacol Ther. 1999; 13:179-86. [PMID: 10102948]
30. Spencer CM, Faulds D. Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders. Drugs. 1994;48:404-30. [PMID: 7527761]
31. Maton PN. Omeprazole. N Engl J Med. 1991;324:965-75. [PMID: 2002819]
32. Valenzuela JE, Berlin RG, Snape WJ, Johnson TL, Hirschowitz BI, Colon-Pagan J, et al. U.S. experience with omeprazole in duodenal ulcer. Multicenter double-blind comparative study with ranitidine. The Omeprazole DU Comparative Study Group. Dig Dis Sci. 1991;36:761-8. [PMID: 2032518]
33. Goldstein JL (on behalf of the CLASS Investigators). Gastrointestinal (GI) event rates in the CLASS study: 6-month vs. longer-term follow-up analysis [Abstract]. Gastroenterology. 2002;122:A469. Abstract no. T1504.
34. Laine L, Peterson WL. Bleeding peptic ulcer. N Engl J Med. 1994;331:717-27. [PMID: 8058080]
35. Lau JY, Sung JJ, Lam YH, Chan AC, Ng EK, Lee DW, et al. Endoscopic retreatment compared with surgery in patients with recurrent bleeding after initial endoscopic control of bleeding ulcers. N Engl J Med. 1999;340:751-6. [PMID: 10072409]
36. Reiertsen O, Skjøtø J, Jacobsen CD, Rosseland AR. Complications of fiberoptic gastrointestinal endoscopy - five years' experience in a central hospital. Endoscopy. 1987;19:1-6. [PMID: 3493897]
37. Quine MA, Bell GD, McCloy RF, Matthews HR. Prospective audit of perforation rates following upper gastrointestinal endoscopy in two regions of England. Br J Surg. 1995;82:530-3. [PMID: 7613903]
38. Arrowsmith JB, Gerstman BB, Fleischer DE, Benjamin SB. Results from the American Society for Gastrointestinal Endoscopy/U.S. Food and Drug Administration collaborative study on complication rates and drug use during gastrointesrinal endoscopy. Gastrointest Endosc. 1991;37:421-7. [PMID: 1833259]
39. Centers for Medicare & Medicaid Services. Medicare Provider Analysis and Review (MEDPAR) of Short-Stay Hospitals. Accessed at www.cms.hhs.gov /statistics/medpar in December 2002.
40. Thijs JC, Van Zwet AA, Oey HB. Efficacy and side effects of a triple drug regimen for the eradication of Helicobacter pylori. Scand J Gastroenterol. 1993; 28:934-8. [PMID: 8284626]
41. de Boer WA, Tytgat GN. The best therapy for Helicobacter pylori infection: should efficacy or side-effect profile determine our choice? Scand J Gastroenterol. 1995;30:401-7. [PMID: 7638563]
42. Soll AH. Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology. JAMA. 1996;275:622-9. [PMID: 8594244]
43. Teare JP, Booth JC, Brown JL, Martin J, Thomas HC. Pseudomembranous colitis following clarithromycin therapy. Eur J Gastroenterol Hepatol. 1995;7: 275-7. [PMID: 7743311]
44. Hirschhorn LR, Trnka Y, Onderdonk A, Lee ML, Platt R. Epidemiology of community-acquired Clostridium difficile-associated diarrhea. J Infect Dis. 1994; 169:127-33. [PMID: 8277174]
45. Malfertheiner P. Compliance, adverse events and antibiotic resistance in Helicobacter pylori treatment. Scand J Gastroenterol Suppl. 1993;196:34-7. [PMID: 8341989]
46. Bensen WG, Fiechtner JJ, McMillen JI, Zhao WW, Yu SS, Woods EM, et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc. 1999;74:1095-105. [PMID: 10560596]
47. Cannon GW, Caldwell JR, Holt P, McLean B, Seidenberg B, Bolognese J, et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group. Arthritis Rheum. 2000;43:978-87. [PMID: 10817549]
48. Day R, Morrison B, Luza A, Castaneda O, Strusberg A, Nahir M, et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group. Arch Intern Med. 2000; 160:1781-7. [PMID: 10871971]
49. Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet. 1999;354:2106-11. [PMID: 10609815]
50. Geusens PP, Truitt K, Sfikakis P, Zhao PL, DeTora L, Shingo S, et al. A placebo and active comparator-controlled trial of rofecoxib for the treatment of rheumatoid arthritis. Scand J Rheumatol. 2002;31:230-8. [PMID: 12369656]
51. Goldstein JL, Correa P, Zhao WW, Burr AM, Hubbard RC, Verburg KM, et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol. 2001;96:1019-27. [PMID: 11316141]
52. Goldstein JL, Agrawal N, Eisen GM, Stenson W, Bello AE, Fort JG, et al. Significantly improved upper gastrointestinal (UGI) tolerability with celecoxib, a COX-2 specific inhibitor, compared with conventional NSAIDs: the SUCCESS I trial [Abstract]. Gastroenterology. 2001;120:A105. Abstract no. 555.
53. Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H, et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology. 1999;117:776-83. [PMID: 10500058]
54. McKenna F, Borenstein D, Wendt H, Wallemark C, Lefkowith JB, Geis GS. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand J Rheumatol. 2001;30:11-8. [PMID: 11252686]
55. Saag K, van der Heijde D, Fisher C, Samara A, DeTora L, Bolognese J, et al. Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Osteoarthritis Studies Group. Arch Fam Med. 2000;9:1124-34. [PMID: 11115219]
56. Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA. 1999;282:1921-8. [PMID: 10580457]
57. Petitti DB. Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis: Methods for Quantitative Synthesis in Medicine. New York: Oxford Univ Pr; 2000.
58. Knill-Jones R, Drummond M, Kohli H, Davies L. Economic evaluation of gastric ulcer prophylaxis in patients with arthritis receiving non-steroidal anti-inflammatory drugs. Postgrad Med J. 1990;66:639-46. [PMID: 2120690]
59. AI MJ, Michel BC, Rutten FF. The cost effectiveness of diclofenac plus misoprostol compared with diclofenac monotherapy in patients with rheumatoid arthritis. Pharmacoeconomics. 1996;10:141-51. [PMID: 10163417]
60. Maetzel A, Ferraz MB, Bombardier C. The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs. Arthritis Rheum. 1998;41:16-25. [PMID: 9433865]
61. Pellissier JM, Straus WL, Watson DJ, Kong SX, Harper SE. Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritis. Clin Ther. 2001;23:1061-79. [PMID: 11519771]
62. Fendrick AM, Bandekar RR, Chernew ME, Scheiman JM. Role of initial NSAID choice and patient risk factors in the prevention of NSAID gastropathy: a decision analysis. Arthritis Rheum. 2002;47:36-43. [PMID: 11932876]
63. Gold MR, Siegel JE, Russell LB, Weinstein MG, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford Univ Pr; 1996.
64. Groeneveld PW, Lieu TA, Fendrick AM, Hurley LB, Ackerson LM, Levin TR, et al. Quality of life measurement clarifies the cost-effectiveness of Helicobacter pylori eradication in peptic ulcer disease and uninvestigated dyspepsia. Am J Gastroenterol. 2001;96:338-47. [PMID: 11232673]
65. 2002 Red Book. Montvale, NJ: Thomson Medical Economics; 2002.
66. Muennig P. Designing and Conducting Cost-Effectiveness Analyses in Medicine and Health Care. San Francisco: Jossey-Bass; 2002.
67. Chan FK, Chung SC, Suen BY, Lee YT, Leung WK, Leung VK, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med. 2001;344:967-73. [PMID: 11274623]
68. Chan FK, Hung LC, Suen BY, Wu JC, Lee KC, Leung VK, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med. 2002;347:2104-10. [PMID: 12501222]
69. Tsevat J, Goldman L, Soukup JR, Lamas GA, Connors KF, Chapin CC, et al. Stability of time-tradeoff utilities in survivors of myocardial infarction. Med Decis Making. 1993;13:161-5. [PMID: 8483401]
70. Eckman MH, Levine HJ, Pauker SG. Effect of laboratory variation in the prothrombin-time ratio on the results of oral anticoagulant therapy. N Engl J Med. 1993;329:696-702. [PMID: 8135917]
71. Lieu TA, Gurley RJ, Lundstrom RJ, Ray GT, Fireman BH, Weinstein MC, et al. Projected cost-effectiveness of primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 1997;30:1741-50. [PMID: 9385902]
72. Moore RD, Chaisson RE. Cost-utility analysis of prophylactic treatment with oral ganciclovir for cytomegalovirus retinitis. J Acquir Immune Defic Syndr Hum Retrovirol. 1997; 16:15-21. [PMID: 9377120]
73. Hamel MB, Phillips RS, Davis RB, Teno J, Connors AF, Desbiens N, et al. Outcomes and cost-effectiveness of ventilator support and aggressive care for patients with acute respiratory failure due to pneumonia or acute respiratory distress syndrome. Am J Med. 2000; 109:614-20. [PMID: 11099680]
74. Hamel MB, Phillips RS, Davis RB, Desbiens N, Connors AF Jr, Teno JM, et al. Outcomes and cost-effectiveness of initiating dialysis and continuing aggressive care in seriously ill hospitalized adults. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. Ann Intern Med. 1997;127:195-202. [PMID: 9245224]
75. Lai K-C, Chu K-M, Hui W-M, Wong C-Y, Hu W, Yuen W-M, et al. COX-2 inhibitor compared with proton pump inhibitor in the prevention of recurrent ulcer complications in high-risk patients taking NSAIDs [Abstract]. Gastroenterology. 2001;120:A104. Abstract no. 551.
76. Cantor SB. Pharmacoeconomics of coxib therapy. J Pain Symptom Manage. 2002;24:S28-37. [PMID: 12204485]
77. Mamdani M, Rochon PA, Juurlink DN, Kopp A, Anderson GM, Naglie G, et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ. 2002;325:624. [PMID: 12242172]
78. Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ. 2002;325:619. [PMID: 12242171]
79. Geba GP, Weaver AL, Polis AB, Dixon ME, Schnitzer TJ. Efficacy of rofecoxib, celecoxib, and aceraminophen in osteoarthritis of the knee: a randomized trial. JAMA. 2002;287:64-71. [PMID: 11754710]
80. Schnitzer T, Kong S, Mitchell J, et al. Prescription of rofecoxib and celecoxib by physician specialty for patients with osteoarthritis and rheumatoid arthritis category [Abstract]. Arthritis and Rheumatism 2002;46:A326.
81. Weideman RA, Kelly KC, Kelley CL, Cryer B. COX-2-specific inhibitors: prescribing patterns in a large managed care health system and strategies to minimize costs. Am J Manag Care. 2002;8:869-77. [PMID: 12395955]
82. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med. 2002;136:157. [PMID: 11790071]
83. Centers for Disease Control and Prevention, National Center for Health Statistics. National Vital Statistics Report. Accessed at www.cdc.gov/nchs in December 2002.
84. Ebell MH, Warbasse L, Brenner C. Evaluation of the dyspeptic patient: a cost-utiliry study. J Fam Pract. 1997;44:545-55. [PMID: 9191627]
85. Sonnenberg A, Everhart JE. Health impact of peptic ulcer in the United States. Am J Gastroenterol. 1997;92:614-20. [PMID: 9128309]
86. Revicki DA, Wood M. Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications. J Affect Disord. 1998;48:25-36. [PMID: 9495599]
87. Kuntz KM, Fleischmann KE, Hunink MG, Douglas PS. Cost-effectiveness of diagnostic strategies for patients with chest pain. Ann Intern Med. 1999;130: 709-18. [PMID: 10357689]
88. Lawrence WF, Fryback DG, Martin PA, Klein R, Klein BE. Health status and hypertension: a population-based study. J Clin Epidemiol. 1996;49:1239-45. [PMID: 8892491]
89. Spiegel BM, Vakil NB, Ofman JJ. Dyspepsia management in primary care: a decision analysis of competing strategies. Gastroenterology. 2002;122:1270-85. [PMID: 11984514]
90. Sanders GD, Hlatky MA, Every NR, McDonald KM, Heidenreich PA, Parsons LS, et al. Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator of amiodarone after myocardial infarction. Ann Intern Med. 2001;135:870-83. [PMID: 11712877]
91. Nyman JA, Martinson MS, Nelson D, Nugent S, Collins D, Wittes J, et al. Cost-effectiveness of gemfibrozil for coronary heart disease patients with low levels of high-density lipoprotein cholesterol: the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial. Arch Intern Med. 2002;162:177-82. [PMID: 11802751]